{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:28:56Z","timestamp":1780363736901,"version":"3.54.1"},"reference-count":24,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T00:00:00Z","timestamp":1730332800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Farmacia Hospitalaria"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.farma.2024.10.017","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T21:10:34Z","timestamp":1732914634000},"page":"200-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis"],"prefix":"10.1016","volume":"49","author":[{"given":"Joaqu\u00edn","family":"Borr\u00e1s-Blasco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Cornejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Valcuende-Rosique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebeca","family":"Alcala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Navalon","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"323","key":"10.1016\/j.farma.2024.10.017_bb0005","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: a review","volume":"19","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.farma.2024.10.017_bb0010","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.det.2024.02.001","article-title":"Biologics for psoriasis","volume":"42","author":"Wride","year":"2024","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.farma.2024.10.017_bb0015","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.det.2024.02.006","article-title":"The psoriasis treatment pipeline: an overview and update","volume":"42","author":"Hawkes","year":"2024","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.farma.2024.10.017_bb0025","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1007\/s13555-022-00740-y","article-title":"Utilization trends and impact of secukinumab treatment on clinical outcomes in biologic-naive patients with psoriasis in a US real-world setting","volume":"12","author":"Strober","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.farma.2024.10.017_bb0030","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/14740338.2016.1221923","article-title":"Safety of in the treatment of psoriasis","volume":"15","author":"Blauvelt","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.farma.2024.10.017_bb0035","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"BADBIR Study Group. Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.farma.2024.10.017_bb0040","doi-asserted-by":"crossref","first-page":"T141","DOI":"10.1016\/j.farma.2023.07.020","article-title":"Persistence: the current state of the art","volume":"48","author":"Rodriguez Goicoechea","year":"2024","journal-title":"Farm Hosp"},{"key":"10.1016\/j.farma.2024.10.017_bb0045","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5021\/ad.22.003","article-title":"Available alternative biologics and disease groups influence biologic drug survival in patients with psoriasis and psoriatic arthritis","volume":"34","author":"Oh","year":"2022","journal-title":"Ann. Dermatol."},{"key":"10.1016\/j.farma.2024.10.017_bb0050","first-page":"16","article-title":"Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis","volume":"45","author":"Conesa-Nicol\u00e1s","year":"2020","journal-title":"Farm Hosp"},{"key":"10.1016\/j.farma.2024.10.017_bb0055","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1159\/000250839","article-title":"Severe psoriasis\u2014oral therapy with a new retinoid","volume":"157","author":"Fredriksson","year":"1978","journal-title":"Dermatologica"},{"key":"10.1016\/j.farma.2024.10.017_bb0060","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.farma.2024.10.017_bb0065","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1111\/jdv.15600","article-title":"Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis","volume":"33","author":"De la Cueva","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.farma.2024.10.017_bb0070","first-page":"62","article-title":"Adherence to treatment with adalimumab, golimumab and ustekinumab in patients with inflammatory bowel disease","volume":"44","author":"Calvo-Arbeloa","year":"2020","journal-title":"Farm Hosp"},{"key":"10.1016\/j.farma.2024.10.017_bb0075","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jhqr.2023.10.005","article-title":"El valor de la persistencia en el modelo de la Medicina 5P en enfermedades cr\u00f3nicas [The value of persistence in the 5P Medicine model for chronic diseases]","volume":"39","author":"Borras-Blasco","year":"2024","journal-title":"J Healthc Qual Res"},{"key":"10.1016\/j.farma.2024.10.017_bb0080","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jdv.16202","article-title":"Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response","volume":"34","author":"Rompoti","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.farma.2024.10.017_bb0085","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1111\/jdv.18329","article-title":"Secukinumab demonstrated sustained retention, effectiveness and safety in a real-world setting in patients with moderate-to-severe plaque psoriasis: long-term results from an interim analysis of the SERENA study","volume":"36","author":"Augustin","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.farma.2024.10.017_bb0090","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s13555-021-00606-9","article-title":"Multi-center retrospective study of secukinumab drug survival in psoriasis patients in a daily practice setting: a long-term experience in Spain","volume":"11","author":"Daud\u00e9n","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.farma.2024.10.017_bb0095","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5114\/ada.2023.135757","article-title":"Long-term efficacy, safety, and drug survival of secukinumab in patients with psoriasis in Turkey: a retrospective analysis of real-world experience","volume":"41","author":"Y\u0131ld\u0131r\u0131m","year":"2024","journal-title":"Postepy. Dermatol. Alergol."},{"key":"10.1016\/j.farma.2024.10.017_bb0100","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2200868","article-title":"Long-term efficacy and safety of secukinumab in real life: a 240 weeks multicenter study from Southern Italy","volume":"34","author":"Dastoli","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.farma.2024.10.017_bb0105","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1111\/ajd.14153","article-title":"Real-world treatment persistence of four commonly prescribed biologic therapies for moderate to severe psoriasis in Australia","volume":"64","author":"Sullivan","year":"2023","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.farma.2024.10.017_bb0110","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1080\/14712598.2023.2194485","article-title":"Guselkumab for treatment of moderate-to-severe plaque psoriasis: real-life effectiveness and drug-survival for up to 148 weeks","volume":"23","author":"Galluzzo","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.farma.2024.10.017_bb0115","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s13555-021-00616-7","article-title":"Drug persistence of biologic treatments in psoriasis: a Swedish national population study","volume":"11","author":"Schmitt-Egenolf","year":"2021","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.farma.2024.10.017_bb0120","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2023.2229465","article-title":"Treatment persistence of interleukin-17 inhibitor class drugs among patients with psoriasis in Japan: a retrospective database study","volume":"34","author":"Wang","year":"2023","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.farma.2024.10.017_bb0125","doi-asserted-by":"crossref","DOI":"10.1093\/intqhc\/mzae026","article-title":"Integration of persistence in the 5P-medicine approach for age-related chronic diseases","volume":"36","author":"Borr\u00e1s-Blasco","year":"2024","journal-title":"International J Qual Health Care"}],"container-title":["Farmacia Hospitalaria"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324001764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1130634324001764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T23:49:08Z","timestamp":1770680948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1130634324001764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1130634324001764"],"URL":"https:\/\/doi.org\/10.1016\/j.farma.2024.10.017","relation":{},"ISSN":["1130-6343"],"issn-type":[{"value":"1130-6343","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term persistence with secukinumab in patients with moderate-to-severe psoriasis","name":"articletitle","label":"Article Title"},{"value":"Farmacia Hospitalaria","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.farma.2024.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Farmacia Hospitalaria (S.E.F.H). Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}